B型肝炎ウイルス（HBV）の世界市場レポート 2025年

B型肝炎ウイルス（HBV）市場規模は、今後数年間で力強い成長が見込まれます。2029年にはCAGR9.8％で107億2,000万米ドルに成長します。予測期間の成長は、個別化医療の台頭、患者擁護団体からの支持の高まり、ワクチン接種プログラムの増加、ヘルスケア支出の増加に起因しています。予測期間における主な動向としては、新薬の開発、診断技術の進歩、官民パートナーシップ、革新的な生物学的療法などが挙げられます。

B型肝炎感染の高い有病率が、今後数年間のB型肝炎ウイルス市場の成長を促進すると予想されます。B型肝炎は、B型肝炎ウイルス（HBV）によって引き起こされる肝臓感染症であり、ワクチン接種によって予防することができます。B型肝炎感染率の増加は、診断検査や治療オプションの需要を高める可能性が高いです。例えば、2024年4月、スイスに本部を置く政府間機関である世界保健機関（WHO）は、2022年には2億5,400万人が慢性B型肝炎に罹患しており、毎年120万人が新たにB型肝炎に罹患していると報告しました。その結果、B型肝炎感染の高い有病率は、B型肝炎ウイルス市場に大きな影響を与えると予想されます。

肝障害や肝硬変を経験する患者数の増加が、今後のB型肝炎ウイルス市場の成長を促進すると予想されます。肝硬変は、健康な肝組織が瘢痕組織で永久的に置き換わることを特徴とする重篤な肝疾患です。B型肝炎ウイルスは、この疾患に伴う症状や副作用を緩和しながら、腎機能に影響を与えることができます。例えば、2023年7月、英国政府部門のOffice for Health Improvement and Disparitiesは、2022年会計年度において、イングランドでは肝疾患による入院が82,290件記録され、人口10万人当たり150.6件の割合に相当すると報告しました。これは、2021年に終了する前会計年度の入院患者数67,458人から増加したことを意味し、国民の間で肝臓の健康に対する懸念が高まっていることを浮き彫りにしています。したがって、患者の肝障害や肝硬変の発生率が上昇していることが、B型肝炎ウイルス市場の成長に寄与しています。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場- 金利、インフレ、地政学、コロナ、回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界B型肝炎ウイルス（HBV） PESTEL分析（政治、社会、技術、環境、法的要因、促進要因、抑制要因）
• 最終用途産業の分析
• 世界のB型肝炎ウイルス（HBV）市場：成長率分析
• 世界のB型肝炎ウイルス（HBV）市場の実績：規模と成長, 2019-2024
• 世界のB型肝炎ウイルス（HBV）市場の予測：規模と成長, 2024-2029, 2034F
• 世界B型肝炎ウイルス（HBV）総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界のB型肝炎ウイルス（HBV）市場：タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 急性
• 慢性
• 世界のB型肝炎ウイルス（HBV）市場治療別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 免疫調節薬
• 抗ウイルス薬
• ワクチン
• 手術
• 世界のB型肝炎ウイルス（HBV）市場：年齢層別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 小児科
• 大人
• シニア
• 世界のB型肝炎ウイルス（HBV）市場：エンドユーザー別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 医療提供者
• 患者
• ヘルスケア支払者
• 世界のB型肝炎ウイルス（HBV）市場急性HBVのサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 無症候性急性HBV
• 症状のある急性HBV
• 重症急性HBV
• 世界のB型肝炎ウイルス（HBV）市場慢性HBVのサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 慢性B型肝炎（HBe抗原陽性）
• 慢性B型肝炎（HBe抗原陰性）
• 代償性肝疾患を伴う慢性B型肝炎
• 非代償性肝疾患を伴う慢性B型肝炎
• 肝細胞がん（HCC）を伴う慢性B型肝炎

第7章 地域別・国別分析

• 世界のB型肝炎ウイルス（HBV）市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界のB型肝炎ウイルス（HBV）市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• B型肝炎ウイルス（HBV）市場：競合情勢
• B型肝炎ウイルス（HBV）市場：企業プロファイル
  • Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Johnson & Johnson Services Inc. Overview, Products and Services, Strategy and Financial Analysis
  • F. Hoffmon La Roche Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Bayer AG
• Bristol-Myers Squibb Company
• AstraZeneca PLC
• Sanofi SA
• GlaxoSmithKline PLC
• Takeda Pharmaceutical Company Limited
• Eli Lilly and Company
• Gilead Sciences Inc.
• Boehringer Ingelheim International GmbH
• Mylan N.V.
• Teva Pharmaceutical Industries Ltd.
• Vertex Pharmaceuticals Incorporated
• Eisai Co. Ltd.
• Aurobindo Pharma Limited
• Apotex Corp.

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• B型肝炎ウイルス（HBV）市場2029：新たな機会を提供する国
• B型肝炎ウイルス（HBV）市場2029：新たな機会を提供するセグメント
• B型肝炎ウイルス（HBV）市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Hepatitis B virus (HBV) is a liver-targeting viral infection transmitted through contact with infected blood or bodily fluids, including vertical transmission from mother to child during childbirth. The primary approach to managing HBV involves the use of antiviral medications to suppress viral replication, while vaccination plays a crucial role in prevention.

Hepatitis B virus (HBV) is categorized into acute and chronic forms. Acute hepatitis B is a short-term infection resulting from HBV, typically occurring within the first six months of exposure. The medications for acute cases aim to clear the virus from the body and prevent chronic infection. Treatment options include immune modulator drugs, antiviral medications, vaccines, and, in some cases, surgery. These treatments are administered to individuals across various age groups, including pediatrics, adults, and seniors, with medical providers, patients, and healthcare payers being involved in the healthcare process.

The hepatitis B virus (HBV) market research report is one of a series of new reports from The Business Research Company that provides hepatitis B virus (HBV) market statistics, including hepatitis B virus (HBV) industry global market size, regional shares, competitors with a hepatitis B virus (HBV) market share, detailed hepatitis B virus (HBV) market segments, market trends and opportunities and any further data you may need to thrive in the hepatitis B virus (HBV) industry. This hepatitis B virus (HBV) market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The hepatitis B virus (HBV) market size has grown strongly in recent years. It will grow from $6.71 billion in 2024 to $7.37 billion in 2025 at a compound annual growth rate (CAGR) of 9.9%. The growth in the historic period can be attributed to rising prevalence of hepatitis b virus (hbv), growing demand for hbv diagnostics, expanding hbv vaccine coverage, rising awareness of hepatitis b virus (hbv).

The hepatitis B virus (HBV) market size is expected to see strong growth in the next few years. It will grow to $10.72 billion in 2029 at a compound annual growth rate (CAGR) of 9.8%. The growth in the forecast period can be attributed to the rise of personalized medicine, growing support from patient advocacy groups, rising vaccination programs, increase in healthcare expenditure. Major trends in the forecast period include development of new drugs, advancements in diagnostic technologies, public-private partnerships, innovative biological therapies.

The high prevalence of hepatitis B infections is anticipated to drive the growth of the hepatitis B virus market in the coming years. Hepatitis B is a liver infection caused by the hepatitis B virus (HBV), which can be prevented through vaccination. Increasing rates of hepatitis B infections are likely to elevate the demand for diagnostic tests and treatment options. For instance, in April 2024, the World Health Organization, a Switzerland-based intergovernmental organization, reported that in 2022, 254 million people were living with chronic hepatitis B, with 1.2 million new cases diagnosed each year. Consequently, the high prevalence of hepatitis B infections is expected to significantly influence the hepatitis B virus market.

An increase in the number of patients experiencing liver damage or cirrhosis is expected to drive the growth of the hepatitis B virus market in the future. Cirrhosis is a serious liver disease characterized by the permanent replacement of healthy liver tissue with scar tissue. The hepatitis B virus can impact kidney function while alleviating symptoms and side effects associated with the condition. For example, in July 2023, the Office for Health Improvement and Disparities, a UK government department, reported that in the financial year ending 2022, England recorded 82,290 hospital admissions due to liver disease, equating to a rate of 150.6 per 100,000 people. This marks an increase from 67,458 admissions in the previous financial year ending in 2021, highlighting a growing concern about liver health within the population. Therefore, the rising incidence of liver damage or cirrhosis among patients is contributing to the growth of the hepatitis B virus market.

Prominent companies operating within the hepatitis B virus (HBV) market are placing a strong emphasis on the advancement of cutting-edge diagnostics and treatment options. One such innovation involves the utilization of highly sensitive chemiluminescent microparticle immunoassay (CMIA) technology to gain a competitive edge in the market. A case in point is Abbott Laboratories, a healthcare company based in the United States, which, in May 2022, introduced the HBsAg Next Qualitative Solution Test. This test is designed to facilitate the early detection of the Hepatitis B virus (HBV) in human serum and plasma samples. By enhancing early detection capabilities, this advanced chemiluminescent microparticle immunoassay (CMIA) not only contributes to improved patient outcomes but also safeguards the integrity of blood supplies. It enables both early detection of HBV in human serum and plasma (blood) samples and population screening, all thanks to its highly sensitive technology.

In July 2023, Brii Biosciences Ltd., a biotechnology firm headquartered in China, secured licensing rights for an experimental hepatitis B immunotherapy and an approved hepatitis B vaccine from VBI Vaccines Inc., an American biotechnology company. This transaction, for an undisclosed sum, grants Brii Biosciences Ltd. access to valuable insights related to both the prevention and treatment of hepatitis B. VBI Vaccines Inc. specializes in the development of a vaccine designed to prevent infections caused by the hepatitis B virus.

Major companies operating in the hepatitis b virus (hbv) market are Pfizer Inc., Johnson & Johnson Services Inc., F. Hoffmon La Roche Ltd., Merck & Co. Inc., AbbVie Inc., Bayer AG, Bristol-Myers Squibb Company, AstraZeneca PLC, Sanofi SA, GlaxoSmithKline PLC, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Gilead Sciences Inc., Boehringer Ingelheim International GmbH, Mylan N.V., Teva Pharmaceutical Industries Ltd., Vertex Pharmaceuticals Incorporated, Eisai Co. Ltd., Aurobindo Pharma Limited, Apotex Corp., Lupin Pharmaceuticals Inc., Cadila Healthcare Ltd., Celltrion Inc., Dynavax Technologies Corporation, Accord Healthcare Inc., Par Pharmaceutical Inc., Arrowhead Pharmaceuticals Inc., Arbutus Biopharma Corporation, Globeimmune Inc., Antios Therapeutics Inc.

North America was the largest region in the hepatitis B Virus (HBV) market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in hepatitis B virus (HBV) report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the hepatitis B virus (HBV) market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The hepatitis B virus (HBV) market consists of revenues earned by entities by providing diagnostic testing for infection and monitoring of liver function. The market value includes the value of related goods sold by the service provider or included within the service offering. The hepatitis B virus (HBV) market also includes sales of tenofovir disoproxil, entecavir, telbivudine and lamivudine. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Hepatitis B Virus (HBV) Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on hepatitis b virus (hbv) market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for hepatitis b virus (hbv) ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The hepatitis b virus (hbv) market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Type: Acute; Chronic
• 2) By Treatment: Immune Modulator Drugs; Antiviral Drugs; Vaccine; Surgery
• 3) By Age Group: Pediatrics; Adults; Seniors
• 4) By End User: Medical Providers; Patients; Healthcare Payers
• Subsegments:
• 1) By Acute HBV: Asymptomatic Acute HBV; Symptomatic Acute HBV; Severe Acute HBV
• 2) By Chronic HBV: Chronic Hepatitis B (HBeAg Positive); Chronic Hepatitis B (HBeAg Negative); Chronic Hepatitis B With Compensated Liver Disease; Chronic Hepatitis B With Decompensated Liver Disease; Chronic Hepatitis B With Hepatocellular Carcinoma (HCC)
• Companies Mentioned: Pfizer Inc.; Johnson & Johnson Services Inc.; F. Hoffmon La Roche Ltd.; Merck & Co. Inc.; AbbVie Inc.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Hepatitis B Virus (HBV) Market Characteristics

3. Hepatitis B Virus (HBV) Market Trends And Strategies

4. Hepatitis B Virus (HBV) Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Covid And Recovery On The Market

5. Global Hepatitis B Virus (HBV) Growth Analysis And Strategic Analysis Framework

• 5.1. Global Hepatitis B Virus (HBV) PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Hepatitis B Virus (HBV) Market Growth Rate Analysis
• 5.4. Global Hepatitis B Virus (HBV) Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Hepatitis B Virus (HBV) Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Hepatitis B Virus (HBV) Total Addressable Market (TAM)

6. Hepatitis B Virus (HBV) Market Segmentation

• 6.1. Global Hepatitis B Virus (HBV) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Acute
• Chronic
• 6.2. Global Hepatitis B Virus (HBV) Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Immune Modulator Drugs
• Antiviral Drugs
• Vaccine
• Surgery
• 6.3. Global Hepatitis B Virus (HBV) Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Pediatrics
• Adults
• Seniors
• 6.4. Global Hepatitis B Virus (HBV) Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Medical Providers
• Patients
• Healthcare Payers
• 6.5. Global Hepatitis B Virus (HBV) Market, Sub-Segmentation Of Acute HBV, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Asymptomatic Acute HBV
• Symptomatic Acute HBV
• Severe Acute HBV
• 6.6. Global Hepatitis B Virus (HBV) Market, Sub-Segmentation Of Chronic HBV, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Chronic Hepatitis B (HBeAg Positive)
• Chronic Hepatitis B (HBeAg Negative)
• Chronic Hepatitis B With Compensated Liver Disease
• Chronic Hepatitis B With Decompensated Liver Disease
• Chronic Hepatitis B With Hepatocellular Carcinoma (HCC)

7. Hepatitis B Virus (HBV) Market Regional And Country Analysis

• 7.1. Global Hepatitis B Virus (HBV) Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Hepatitis B Virus (HBV) Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Hepatitis B Virus (HBV) Market

• 8.1. Asia-Pacific Hepatitis B Virus (HBV) Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Hepatitis B Virus (HBV) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Hepatitis B Virus (HBV) Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Hepatitis B Virus (HBV) Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Hepatitis B Virus (HBV) Market

• 9.1. China Hepatitis B Virus (HBV) Market Overview
• 9.2. China Hepatitis B Virus (HBV) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Hepatitis B Virus (HBV) Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Hepatitis B Virus (HBV) Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Hepatitis B Virus (HBV) Market

• 10.1. India Hepatitis B Virus (HBV) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Hepatitis B Virus (HBV) Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Hepatitis B Virus (HBV) Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Hepatitis B Virus (HBV) Market

• 11.1. Japan Hepatitis B Virus (HBV) Market Overview
• 11.2. Japan Hepatitis B Virus (HBV) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Hepatitis B Virus (HBV) Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Hepatitis B Virus (HBV) Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Hepatitis B Virus (HBV) Market

• 12.1. Australia Hepatitis B Virus (HBV) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Hepatitis B Virus (HBV) Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Hepatitis B Virus (HBV) Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Hepatitis B Virus (HBV) Market

• 13.1. Indonesia Hepatitis B Virus (HBV) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Hepatitis B Virus (HBV) Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Hepatitis B Virus (HBV) Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Hepatitis B Virus (HBV) Market

• 14.1. South Korea Hepatitis B Virus (HBV) Market Overview
• 14.2. South Korea Hepatitis B Virus (HBV) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Hepatitis B Virus (HBV) Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Hepatitis B Virus (HBV) Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Hepatitis B Virus (HBV) Market

• 15.1. Western Europe Hepatitis B Virus (HBV) Market Overview
• 15.2. Western Europe Hepatitis B Virus (HBV) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Hepatitis B Virus (HBV) Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Hepatitis B Virus (HBV) Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Hepatitis B Virus (HBV) Market

• 16.1. UK Hepatitis B Virus (HBV) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Hepatitis B Virus (HBV) Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Hepatitis B Virus (HBV) Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Hepatitis B Virus (HBV) Market

• 17.1. Germany Hepatitis B Virus (HBV) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Hepatitis B Virus (HBV) Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Hepatitis B Virus (HBV) Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Hepatitis B Virus (HBV) Market

• 18.1. France Hepatitis B Virus (HBV) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Hepatitis B Virus (HBV) Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Hepatitis B Virus (HBV) Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Hepatitis B Virus (HBV) Market

• 19.1. Italy Hepatitis B Virus (HBV) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Hepatitis B Virus (HBV) Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Hepatitis B Virus (HBV) Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Hepatitis B Virus (HBV) Market

• 20.1. Spain Hepatitis B Virus (HBV) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Hepatitis B Virus (HBV) Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Hepatitis B Virus (HBV) Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Hepatitis B Virus (HBV) Market

• 21.1. Eastern Europe Hepatitis B Virus (HBV) Market Overview
• 21.2. Eastern Europe Hepatitis B Virus (HBV) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Hepatitis B Virus (HBV) Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Hepatitis B Virus (HBV) Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Hepatitis B Virus (HBV) Market

• 22.1. Russia Hepatitis B Virus (HBV) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Hepatitis B Virus (HBV) Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Hepatitis B Virus (HBV) Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Hepatitis B Virus (HBV) Market

• 23.1. North America Hepatitis B Virus (HBV) Market Overview
• 23.2. North America Hepatitis B Virus (HBV) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Hepatitis B Virus (HBV) Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Hepatitis B Virus (HBV) Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Hepatitis B Virus (HBV) Market

• 24.1. USA Hepatitis B Virus (HBV) Market Overview
• 24.2. USA Hepatitis B Virus (HBV) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Hepatitis B Virus (HBV) Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Hepatitis B Virus (HBV) Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Hepatitis B Virus (HBV) Market

• 25.1. Canada Hepatitis B Virus (HBV) Market Overview
• 25.2. Canada Hepatitis B Virus (HBV) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Hepatitis B Virus (HBV) Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Hepatitis B Virus (HBV) Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Hepatitis B Virus (HBV) Market

• 26.1. South America Hepatitis B Virus (HBV) Market Overview
• 26.2. South America Hepatitis B Virus (HBV) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Hepatitis B Virus (HBV) Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Hepatitis B Virus (HBV) Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Hepatitis B Virus (HBV) Market

• 27.1. Brazil Hepatitis B Virus (HBV) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Hepatitis B Virus (HBV) Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Hepatitis B Virus (HBV) Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Hepatitis B Virus (HBV) Market

• 28.1. Middle East Hepatitis B Virus (HBV) Market Overview
• 28.2. Middle East Hepatitis B Virus (HBV) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Hepatitis B Virus (HBV) Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Hepatitis B Virus (HBV) Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Hepatitis B Virus (HBV) Market

• 29.1. Africa Hepatitis B Virus (HBV) Market Overview
• 29.2. Africa Hepatitis B Virus (HBV) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Hepatitis B Virus (HBV) Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Hepatitis B Virus (HBV) Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Hepatitis B Virus (HBV) Market Competitive Landscape And Company Profiles

• 30.1. Hepatitis B Virus (HBV) Market Competitive Landscape
• 30.2. Hepatitis B Virus (HBV) Market Company Profiles
  • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Johnson & Johnson Services Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. F. Hoffmon La Roche Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis

31. Hepatitis B Virus (HBV) Market Other Major And Innovative Companies

• 31.1. Bayer AG
• 31.2. Bristol-Myers Squibb Company
• 31.3. AstraZeneca PLC
• 31.4. Sanofi SA
• 31.5. GlaxoSmithKline PLC
• 31.6. Takeda Pharmaceutical Company Limited
• 31.7. Eli Lilly and Company
• 31.8. Gilead Sciences Inc.
• 31.9. Boehringer Ingelheim International GmbH
• 31.10. Mylan N.V.
• 31.11. Teva Pharmaceutical Industries Ltd.
• 31.12. Vertex Pharmaceuticals Incorporated
• 31.13. Eisai Co. Ltd.
• 31.14. Aurobindo Pharma Limited
• 31.15. Apotex Corp.

32. Global Hepatitis B Virus (HBV) Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Hepatitis B Virus (HBV) Market

34. Recent Developments In The Hepatitis B Virus (HBV) Market

35. Hepatitis B Virus (HBV) Market High Potential Countries, Segments and Strategies

• 35.1 Hepatitis B Virus (HBV) Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Hepatitis B Virus (HBV) Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Hepatitis B Virus (HBV) Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer